Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares

Authors
Choi, Hyo JinLee, Chan HeeLee, Joo HyunYoon, Bo YoungKim, Hyoun AhSuh, Chang HeeChoi, Sang TaeSong, Jung SooJoo, Ho YeonChoi, Sung JaeLee, Ji SooShin, Kee ChulBaek, Han Joo
Issue Date
4월-2017
Publisher
WILEY
Keywords
flare; gout treatment; prophylactic duration; serum uric acid
Citation
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, v.20, no.4, pp.497 - 503
Indexed
SCIE
SCOPUS
Journal Title
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
Volume
20
Number
4
Start Page
497
End Page
503
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/84043
DOI
10.1111/1756-185X.12422
ISSN
1756-1841
Abstract
Aim: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. Methods: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. Results: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it >= 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the >= 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Conclusions: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE